Oncolytics Biotech Inc. ONC.TO
Set alert
As of Aug 22, 4:00 PM ET
- Open
- 1.42
- Prev close
- 1.42
- Mkt cap
- 99.43M
- Vol
- 109.63K
- Avg vol
- 144.82K
- EPS
- -0.36
- P/E
- -3.84
- Div yield
- 0.00%
More statistics
- Low
- 1.39
- High
- 1.44
- Forward P/E
- -3.07
- Beta
- 1.51
- Short ratio
- 2.20
- Inst. own
- 1.76%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.45
- 200-d avg
- 1.43
- 1y target
- 6.75
Key statistics
- Market cap
- 99.43M
- Enterprise value
- 89.44M
- Trailing P/E
- 0.00
- Forward P/E
- -3.07
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.49
- EPS (TTM)
- -0.36
- Beta
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -15.77M
- Total cash
- 24.85M
- Total debt
- 1.12M
- Return on equity
- -138.22%
- Shares outstanding
- 77.07M
- Short % of float
- 0.61%
- 50-day average
- 1.45
- 200-day average
- 1.43
Analyst view
Consensus: none
- Target (low)
- 3.50
- Target (mean)
- 6.75
- Target (high)
- 9.00
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.1345.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 4, 2024 | Raymond James | init | — | Outperform |
| Mar 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- oncolyticsbiotech.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ONC.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| International Assets Investment Management, LLC | 0.26% | 198,400 | 255.94K | Jun 29, 2024 |
| Seeds Investor LLC | 0.25% | 189,941 | 245.02K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.11% | 84,998 | 109.65K | Sep 29, 2024 |
| Royal Bank of Canada | 0.10% | 74,546 | 96.16K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 79,249 | 102.23K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.08% | 61,114 | 78.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 41,942 | 54.10K | Oct 30, 2024 |